No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific region, and other international markets. MedMira offers a diverse portfolio of rapid diagnostic tests and technology platforms. Its diagnostic solutions include Reveal HIV, which identifies HIV-1 and HIV-2 antibodies in various blood samples; Reveal TP, a rapid test for syphilis antibodies (Treponema pallidum); and Reveal HP, designed to detect Helicobacter pylori antibodies. The company also provides Multiplo, a line of multiplex tests for combined screening of conditions such as HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. In the realm of respiratory and viral diagnostics, MedMira developed VYRA CoV2 for SARS-CoV-2 nucleocapsid antigen detection, VYRA CoV2Flu for simultaneous antigen testing of SARS-CoV-2, Influenza A, and Influenza B, and REVEALCOVID-19, an antibody test for COVID-19. Beyond diagnostic kits, MedMira provides the Miriad RVF toolkit, a platform that facilitates the development and market entry of rapid diagnostics. MedMira distributes its offerings through a wide network of medical distributors and strategic partners. Its customer base is broad, serving various segments of the healthcare industry, including clinical laboratories, hospitals, point-of-care clinics, government agencies, humanitarian aid groups, and public health bodies. The company was established in 1993, is headquartered in Halifax, Canada, and operates as a subsidiary of MedMira Holding AG.

• Chiome Bioscience Inc.
• Estrella Immunopharma, Inc.
• Mabion S.A.
• BeyondSpring Inc.
• Arecor Therapeutics plc
• Botanix Pharmaceuticals Limited
• Lukas Biomedical Inc.
• Molecure S.A.